Blood pressure medication recall expands due to concern over possible cancer-causing ingredient

(WHDH) — The manufacturer of a number of popular blood pressure medications has expanded its recall for two products after a possible cancer-causing ingredient was found in the tablets, according to the U.S. Food and Drug Administration.

Torrent Pharmaceuticals Limited’s recall now includes an additional 36 lots of Losartan Potassium Tablets USP and 68 lots of Losartan Potassium/hydrochlorothiazide tablets USP.

The fourth recall now was prompted by the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient manufactured by Hetero Labs Limited, the FDA said.

Torrent is only recalling lots of losartan-containing products that contain N-Methylnitrosobutyric acid above the acceptable daily intake levels released by the FDA.

Losartan is used to treat hypertension, hypertensive patients with Left Ventricular Hypertrophy and for the treatment of nephropathy in Type 2 diabetic patients. Losartan potassium and hydrochlorothiazide tablets USP is used to treat hypertension and hypertensive patients with Left Ventricular Hypertrophy.

Patients who are taking Losartan Potassium Tablets, USP and Losartan Potassium/Hydrochlorothiazide Tablets USP should continue taking their medication, as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment.

Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication.

An initial recall was issued in December, followed by two more in January.

Below is a list of all the products included in the recall:

(Copyright (c) 2026 Sunbeam Television. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed.)